Gene Rearrangement clinical trials at UCSD
1 in progress, 0 open to eligible people
Showing trials for
Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
Sorry, not currently recruiting here
This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 16 mg futibatinib in previously treated CCA harboring FGFR2 gene fusions and other rearrangements.
La Jolla, California and other locations
Our lead scientists for Gene Rearrangement research studies include Burgoyne Adam.
Last updated: